DOCSLIB.ORG

Fall 2005 Seminar Schedule 8-25

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fall 2005 Seminar Schedule 8-25 Research Seminar Series in Cancer and Developmental Biology Spring 2005 Schedule all seminars begin at 8:30 am date speaker title location Jan. 20 Glen Andrews, Ph.D. Mechanisms of Mammalian Zinc Homeostasis B018 SON KUMC Jan. 27 Leslie Heckert, Ph.D. In vivo mapping of SF-1 functional domains B018 SON KUMC Feb. 3 Linheng Li, Ph.D. Cellular and molecular regulation of hematopoetic B018 SON Stowers Institute and intestinal stem cells Feb. 17 Daniel Wagner, Ph.D. Instructions from Mom: Maternal Control of B018 SON Rice Unversity Zebrafish Development Feb. 24 Patrick E. Fields, Ph.D. Epigenetic control of T-cell differentiation B018 SON Yale School of Medicine Mar. 3 Kun-Liang Guan, Ph.D. Regulation of cell growth and cell size by the B018 SON University of Michigan TSC-mTOR pathway Mar. 31 Kristi Neufeld, Ph.D. Exploring the nuclear functions of the tumor B018 SON KU-Lawrence suppressor APC Apr. 14 Colin Stewart, Ph.D. Functional Architecture of the Nucleus in Development, 1050 SON Natl. Cancer Institute Aging and Disease Apr. 21 Raj Kumar, Ph.D. Modeling Human Reproductive Diseases in the Mouse B018 SON KUMC by Genetic Approaches Apr. 28 Trevor Williams, Ph.D. The mammalian AP-2 transcription factor family: key B018 SON Univ. of Colorado HSC regulators of development and tumor suppression May 12 Paul Trainor, Ph.D. Neural crest cells: patterning of an embryonic stem B018 SON Stowers Institute cell-like population during normal and abnormal craniofacial development Division of Cancer and Developmental Biology Department of Pathology and Laboratory Medicine Kansas Masonic Cancer Research Institute Institute of Maternal-Fetal Biology THE UNIVERSITY OF KANSAS MEDICAL CENTER KMCRI Research Seminar Series in Cancer and Developmental Biology Fall 2005 Schedule all seminars begin at 8:30 am (unless otherwise specified) date speaker title location Aug. 18 Kathleen Green, Ph.D. Discriminating Roles: Beyond 1023 Orr Maj. Northwestern Desmosomal Adhesion (note room) Aug. 25 Lee Niswander, Ph.D. Genetic Control of Neural Tube Closure B018 SON UCHSC and Patterning Sept. 8 Daniel Wagner, Ph.D. Instructions from Mom: Maternal B018 SON Rice University Control of Zebrafish Development Sept. 23-24 Greenwald Symposium http://www2.kumc.edu/crs/greenwald/ on Reproduction go to link above for more information Sept. 29 Li Wang, Ph.D. SHP/Ship: How Far Can It Go? B018 SON KUMC Oct. 3 Nelson Horseman, Ph.D. Interpretation of Endocrine Signals: How B018 SON 4:00 p.m. University of Cincinnati Local Factors Mediate Mammary Gland Osborn Lecture Series Development and Homeostasis Oct. 13 Peter Baumann, Ph.D. Chromosome End Protection and B018 SON Stowers Telomere Length Regulation Oct. 20 Mark Van Doren, Ph.D. The gonad as a model for studying organogenesis 1023 Orr Maj. John's Hopkins and sexual dimorphism (note room) Oct. 27 Chunying Du, Ph.D. Regulation of Apoptosis B018 SON Stowers Nov. 3 Gary Stein, Ph.D. Organization of Gene Regulatory B018 SON Univ. of Massachusetts Machinery in Biological Control and Cancer Dec. 8 Doug Engel, Ph.D. Redefining Genetic Epistasis and B018 SON Univ. of Michigan Regulatory Hierarchies in the Post-Genomic Era Division of Cancer and Developmental Biology Department of Pathology and Laboratory Medicine Kansas Masonic Cancer Research Institute Institute of Maternal-Fetal Biology THE UNIVERSITY OF KANSAS MEDICAL CENTER KMCRI Research Seminar Series in Cancer & Developmental Biology Spring 2006 Schedule All seminars begin promptly at 8.30 a.m. Date Name Location Title 1/19/06 Xiaochun Yu, M.D., Ph.D. G032 Cell Cycle Checkpoints and Cancer The Mayo Clinic & Foundation Lied Auditorium 2/02/06 Jerry Workman, Ph.D. G032 Protein Complexes That Modify Chromatin for Transcription Stowers Institute for Medical Research Lied Auditorium 2/16/06 S. Paul Oh, Ph.D. G032 Animal Models for Human Vascular Diseases The University of Florida Lied Auditorium 2/23/06 Yoshiaki Azuma, Ph.D. G032 SUMO Modification and Cell Cycle Regulation The University of Kansas -Lawrence Lied Auditorium 3/09/06 Lothar Hennighausen, Ph.D. G032 Information Networks Controlled by Cytokines: Lessons From The National Institutes of Health Lied Auditorium Cell-Specific Stat5 Gene Knock-Out Mice 3/16/06 Francesco DeMayo, Ph.D. G032 In Vivo Analysis of Molecular Mechanisms Regulating Murine Baylor College of Medicine Lied Auditorium Endometrial Function 3/23/06 Neal Copeland, Ph.D. G032 Recombineering: A Powerful Functional Genomics Tool The National Cancer Institute Lied Auditorium 4/20/06 Barbara Knowles, Ph.D. G032 Unscrambling the Egg: Gamete to Embryo With No New The Jackson Laboratory Lied Auditorium Transcription 4/27/06 Hong Wu, M.D., Ph.D. G032 PTEN, Stem Cells and Tumorigenesis University of California, Los Angeles Lied Auditorium 5/4/06 Frank Rauscher, Ph.D. G032 Macromolecular Enzyme Complexes Which Target Chromatin The Wistar Institute Lied Auditorium and Control Heritable Gene Silencing: Developing Them As New Therapeutic Targets 5/18/06 Emery Bresnick, Ph.D. G013 School of GATA Factor Networks: From Hematopoiesis to Vascular G013 SON University of Wisconsin Nursing Biology Department of Pathology and Laboratory Medicine, BIRCWH Program in Women’s Health, Kansas Masonic Cancer Research Institute, and the Institute of Maternal-Fetal Biology THE UNIVERSITY OF KANSAS MEDICAL CENTER KMCRI Research Seminar Series in Cancer & Developmental Biology Fall 2006 Schedule All seminars begin promptly at 8.30 a.m. Date Name Location Title 8/17/06 Qing-Xiang Amy Sang, Ph.D. G032 Endometase/Matrilysin-2, Biomarker Discovery, & New Ideas Florida State University Lied Auditorium on Human Breast and Prostate Cancer Apoptosis &Invasion 8/24/06 Richard Behringer, Ph.D. G032 Genetic Mechanisms of Morphological Diversity Univ. of Texas M.D. Anderson Cancer Center Lied Auditorium Between Species: Hand of Man, Wing of Bat 9/7/06 Martin M. Matzuk, Ph.D. Wahl Hall West Genetic Dissection of Mammalian Fertility Pathways Baylor College of Medicine Auditorium 9/21/06 Robb Krumlauf, Ph.D. G032 WISE Ways of Regulating Bone Development and Stowers Institute for Medical Research Lied Auditorium Disease 9/28/06 Ameae Walker, Ph.D. G032 S179D Prolactin as a Cancer Therapeutic: Antagonistic University of California - Riverside Lied Auditorium Agony 10/12/06 David Moore, Ph.D. G032 Nuclear Receptors and Stress Responses in the Liver Baylor College of Medicine Lied Auditorium 11/2/06 Celeste Simon, Ph.D. G032 HIFs, Hypoxia and Angiogensis University of Pennsylvania Lied Auditorium 11/9/06 Linzhao Cheng, Ph.D. G032 Human Embryonic Stem Cells: Self-Renewal and Johns Hopkins University Lied Auditorium Hematopoietic Differentiation 11/30/06 John Robertson, Ph.D. G032 Chemotherapy-induced Cell Death University of Kansas Medical Center Lied Auditorium 12/7/06 Terumi Shigematsu, Ph.D. G032 Functional Organization of the Genome by SATB1 in T National Cancer Institute Lied Auditorium Cells and Breast Cancer 12/14/06 Olivier Pourquie, Ph.D. G032 Patterning of the Vertebrate Body Axis Stowers Institute for Medical Research Lied Auditorium Department of Pathology and Laboratory Medicine, BIRCWH Program in Women’s Health, Kansas Masonic Cancer Research Institute, and the Institute of Maternal-Fetal Biology THE UNIVERSITY OF KANSAS MEDICAL CENTER KMCRI Research Seminar Series in Cancer & Developmental Biology Spring 2007 Schedule All seminars begin promptly at 8.30 a.m. in the Lied Auditorium DATE SPEAKER SEMINAR TITLE 1/18/07 John D. Robertson, Ph.D. Chemotherapy-induced Cell Death University of Kansas Medical Center 2/1/07 Gregg L. Semenza, M.D., Ph.D. Hypoxia, HIF-1 and Cancer Johns Hopkins School of Medicine 2/8/07 Ho Yi Mak, Ph.D. Genetic Regulation of Fat Storage in C. Elegans Stowers Institute for Medical Research 2/15/07 Davor Solter, M.D., Ph.D. A Recurring Dilemma: Preformation Versus Epigenesis in Patterning Max-Planck Institute of Immunobiology Early Mouse Embryos 3/8/07 Gail E. Herman, M.D., Ph.D. Analysis of Nsdhl Deficient Mouse Embryos Reveals a Role for Hedgehog Ohio State University Signaling in Early Placental Development 3/29/07 Dale Abrahamson, Ph.D. Development of the Kidney Glomerular Capillary University of Kansas Medical Center 4/12/07 Marshall S. Horwitz, M.D., Ph.D. Genetics of Neutropenia Univ. of Washington School of Medicine 4/19/07 Stephen B. Baylin, M.D. Title to be determined Johns Hopkins School of Medicine 4/26/07 James D. Shull, Ph.D. Genetic Control of Estrogen Action and Estrogen-Induced Tumorigenesis University of Nebraska Medical Center in the Rat Mammary and Pituitary Glands 5/24/07 Terry R. Magnuson, Ph.D. X Chromosome Inactivation & Genome Imprinting Regulated by a Mouse Univ. of North Carolina - Chapel Hill Polycomb Group Protein Department of Pathology and Laboratory Medicine, BIRCWH Program in Women’s Health, Kansas Masonic Cancer Research Institute, and the Institute of Maternal-Fetal Biology THE UNIVERSITY OF KANSAS MEDICAL CENTER KMCRI Research Seminar Series in Cancer & Developmental Biology Fall 2007 Schedule 8.30 a.m., Lied Auditorium DATE SPEAKER SEMINAR TITLE 9/4/07 Nikki L. Cheng, Ph.D. Role of CCL2 Chemokine Signaling in Mammary Carcinoma Progression Vanderbilt University Enhanced by Tgfbr2 Deficient Fibroblasts 9/6/07 Jay L. Hess, M.D., Ph.D. Transcriptional Deregulation by MLL Fusion Proteins University of Michigan 9/20/07 Joseph D. Fontes, Ph.D. The ZXD Gene Family: Novel Regulators of MHC Class II Transcription University of Kansas Medical Center and Beyond 9/27/07 Gregg L. Semenza, M.D., Ph.D. Hypoxia, HIF-1 and Cancer Johns Hopkins University - Baltimore 10/11/07 Michael Gould, Ph.D. Functional Characterization of Non-Coding Breast Cancer Susceptibility University of Wisconsin - Madison Loci 10/18/07 Channing J. Der, Ph.D. Aberrant Ras and Rho GTPase Signaling and Oncogenesis University of North Carolina - Chapel Hill 11/8/07 Gerard Karsenty, M.D., Ph.D.
Load more

Recommended publications
  • Stem Cells in Cancer Initiation and Progression
    REVIEW Stem cells in cancer initiation and progression Jeevisha Bajaj1,2,3,4,EmilyDiaz1,2,3,4, and Tannishtha Reya1,2,3,4 While standard therapies can lead to an initial remission of aggressive cancers, they are often only a transient solution. The resistance and relapse that follows is driven by tumor heterogeneity and therapy-resistant populations that can reinitiate Downloaded from http://rupress.org/jcb/article-pdf/219/1/e201911053/1396574/jcb_201911053.pdf by guest on 09 February 2021 growth and promote disease progression. There is thus a significant need to understand the cell types and signaling pathways that not only contribute to cancer initiation, but also those that confer resistance and drive recurrence. Here, we discuss work showing that stem cells and progenitors may preferentially serve as a cell of origin for cancers, and that cancer stem cells can be key in driving the continued growth and functional heterogeneity of established cancers. We also describe emerging evidence for the role of developmental signals in cancer initiation, propagation, and therapy resistance and discuss how targeting these pathways may be of therapeutic value. Introduction demonstrated in acute myeloid leukemia (AML; Bonnet and Cancers arise from a series of mutations or genomic alterations Dick, 1997; Lapidot et al., 1994). The identification of malignant that provide a cell with an extensive ability to evade pro- stem cells in leukemia initiated a search for similar populations apoptotic and growth-inhibitory signals and to be self-sufficient in solid tumors, and about a decade later, a small population of ingrowthsignalsthatenablethemtodivideendlessly(Nowell, cells with tumor-initiating properties were identified in mam- 1974).
    [Show full text]
  • Conference Program
    Conference Program Note: All Scientific Sessions will be held in the Omni Hotel at 675 L Street. Poster Sessions will be held at the Hard Rock Hotel at the corner of 5th Avenue & L Street. Sunday, January 20 7:00 p.m.-7:10 p.m. Welcoming Remarks 7:10 p.m.-8:00 p.m. Keynote Address Omni Hotel San Diego, Grand Ballroom Metastasis and diversity in breast cancer Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA 8:00 p.m.-9:30 p.m. Opening Reception Monday, January 21 7:00 a.m.-8:00 a.m. Continental Breakfast Omni Hotel San Diego, Art Gallery 8:00 a.m.-10:00 a.m. Session 1: The Soil Session Chairperson: Zena Werb, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA Omni Hotel San Diego, Grand Ballroom Microenvironmental control of bone metastasis Sylvain Provot, INSERM, Paris, France The role of the microenvironment protein cathelicidin LL-37 in pancreatic ductal adenocarcinoma* Christopher Heeschen, Spanish National Cancer Research Centre (CNIO), Madrid, Spain Normalizing tumor cell metabolism in breast cancer metastasis: A novel therapeutic approach Brunhilde Felding-Habermann, Scripps Research Institute, La Jolla, CA Identification of luminal breast cancers that establish a tumor supportive macroenvironment defined by proangiogenic platelets and bone marrow derived cells* Timothy Marsh, Brigham and Women’s Hospital, Boston, MA The extracellular matrix is fertile soil Richard Hynes, Massachusetts Institute of Technology, Cambridge, MA *Short talks from proffered papers Program and Proceedings • January 20-23, 2013 • San Diego, CA 7 Program 10:00 a.m.-10:30 a.m.
    [Show full text]
  • Immunology Program Seminar Speakers 1994-1995 Through 2018-2019
    Immunology Program Seminar Speakers 1994-1995 through 2018-2019 Speaker Host Date Institution 2018-19 Miriam Merad, MD, PhD ZOU (co-sponsor) 9/6/18 Icahn School of Medicine at Mount Sinai Anand Balasubramani, PhD ZOU (co-sponsor) 9/6/18 AAAS Lenette Lu, MD, PhD MARKOVITZ (co-sponsor) 9/12/18 Massachusettes General Hospital Michail Lionakis, MD, ScD MARKOVITZ (co-sponsor) 10/10/18 NIH/NIAID Brian Rudd, MPH, PhD LUKACS 11/7/18 Cornell University Fred Finkelman, MD HOGAN 11/28/18 Cincinnati Children’s Hospital Michael Barry, PhD Ashley Munie 12/5/18 Mayo Clinic John Varga, MD FOX 1/9/19 Northwestern University Rachael Clark, MD GUDJONSSON 1/16/19 Brigham & Women’s Hospital Irah King, PhD SEGAL 3/20/19 McGill University Wilson Wong, PhD LEI 5/1/19 Boston University Thomas Rothstein, MD, PhD MAO-DRAAYER 5/29/19 Western Michigan University 2017-18 Avery August, PhD LUKACS 9/6/17 Cornell University Javier Carrero, PhD G. MARTINEZ-COLON 9/27/17 Washington University – St. Louis Russell Jones, PhD C. CHANG 10/11/17 McGill University John Cambier, PhD GRIGOROVA 11/15/17 University of Colorado Bernard Fox, PhD LI 2/7/18 Oregon Health & Science University Tannishtha Reya, PhD O’RIORDAN 2/21/18 University of California, San Diego Richard Bucala, MD GOLDSTEIN 3/21/18 Yale University Kristin Hogquist, PhD CARTY 4/4/18 University of Minnesota 2016-17 George Dubyak, PhD KAHLENBERG 9/7/16 Case Western University Daniel Stetson, PhD O’RIORDAN 9/21/16 University of Washington Alyssa Hasty, PhD D.
    [Show full text]
  • UC San Diego UC San Diego Previously Published Works
    UC San Diego UC San Diego Previously Published Works Title Stem cells in cancer initiation and progression. Permalink https://escholarship.org/uc/item/2hj4855g Journal The Journal of cell biology, 219(1) ISSN 0021-9525 Authors Bajaj, Jeevisha Diaz, Emily Reya, Tannishtha Publication Date 2020 DOI 10.1083/jcb.201911053 Peer reviewed eScholarship.org Powered by the California Digital Library University of California REVIEW Stem cells in cancer initiation and progression Jeevisha Bajaj1,2,3,4,EmilyDiaz1,2,3,4, and Tannishtha Reya1,2,3,4 While standard therapies can lead to an initial remission of aggressive cancers, they are often only a transient solution. The resistance and relapse that follows is driven by tumor heterogeneity and therapy-resistant populations that can reinitiate growth and promote disease progression. There is thus a significant need to understand the cell types and signaling pathways that not only contribute to cancer initiation, but also those that confer resistance and drive recurrence. Here, we discuss work showing that stem cells and progenitors may preferentially serve as a cell of origin for cancers, and that cancer stem cells can be key in driving the continued growth and functional heterogeneity of established cancers. We also describe emerging evidence for the role of developmental signals in cancer initiation, propagation, and therapy resistance and discuss how targeting these pathways may be of therapeutic value. Introduction demonstrated in acute myeloid leukemia (AML; Bonnet and Cancers arise from a series of mutations or genomic alterations Dick, 1997; Lapidot et al., 1994). The identification of malignant that provide a cell with an extensive ability to evade pro- stem cells in leukemia initiated a search for similar populations apoptotic and growth-inhibitory signals and to be self-sufficient in solid tumors, and about a decade later, a small population of ingrowthsignalsthatenablethemtodivideendlessly(Nowell, cells with tumor-initiating properties were identified in mam- 1974).
    [Show full text]
  • Report of Science at Williams 2019
    Report of Science at Williams College 2018-2019 A record of the professional and academic activites of faculty and students in the natural sciences Williamstown, Massachusetts Front Cover Image: In Computer Science it is often desirable to generate "all possibilities" of one kind or another. For example, when solving a scheduling problem, each permutation of {1,2,3,4,5} represents a different order in which five jobs can be scheduled for completion. Alternatively, when solving a traveling salesman problem, the same permutations repre- sent the orders in which five cities can be visited. When efficiency is a concern, the order in which the possibilities are generated can become important. Typically, we want each possibility to be similar to the previous possibility, so that any associated values can be updated from object to object, rather than being recomputed from scratch for every object. These types of orders are known as minimal-change orders, or Gray codes. The cover illustrates a minimal-change order the 120 different permutations of {1,2,3,4,5}. If superimposed on a clock, the minute hand would move from one permutation to the next every thirty seconds, starting with 12345 at the top each hour, and ending back at 54321. In this order consecutive permutations differ by a suffix-reversal, meaning that some number of the final (i.e. innermost) values have their order reversed, such as 12345 turning into 123_54_, and then 12354 turning into 12_453_, and so on. (This type of change is "minimal" in the sense that only one pair of adjacent symbols is added and removed, making it useful in the context of bonded structures like DNA, or paths in undirected graphs.) Interestingly, there is a simple rule that describes how to change the most recent permutation into the next: Reverse the shortest suffix that doesn't produce an earlier permutation.
    [Show full text]
  • Stem Cells, Cancer, and Cancer Stem Cells
    insight review articles Stem cells, cancer, and cancer stem cells Tannishtha Reya*§||, Sean J. Morrison†||, Michael F. Clarke‡ & Irving L. Weissman* *Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Palo Alto, California 94305, USA (e-mail: [email protected]) †Howard Hughes Medical Institute, and Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109-0934, USA ‡Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109-0936, USA §Present address: Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA ||These authors contributed equally to this work Stem cell biology has come of age. Unequivocal proof that stem cells exist in the haematopoietic system has given way to the prospective isolation of several tissue-specific stem and progenitor cells, the initial delineation of their properties and expressed genetic programmes, and the beginnings of their utility in regenerative medicine. Perhaps the most important and useful property of stem cells is that of self-renewal. Through this property, striking parallels can be found between stem cells and cancer cells: tumours may often originate from the transformation of normal stem cells, similar signalling pathways may regulate self-renewal in stem cells and cancer cells, and cancer cells may include ‘cancer stem cells’ — rare cells with indefinite potential for self-renewal that drive tumorigenesis. tem cells are defined as cells that have the tumours might contain ‘cancer stem cells’ — rare cells with ability to perpetuate themselves through self- indefinite proliferative potential that drive the formation renewal and to generate mature cells of a and growth of tumours.
    [Show full text]
  • Stem Cells, Development, and Cancer March 3-6, 2011 the Fairmont Hotel Vancouver Vancouver, BC, Canada
    An AACR Special Conference on Stem Cells, Development, and Cancer March 3-6, 2011 The Fairmont Hotel Vancouver Vancouver, BC, Canada Thursday, March 3 7:00 p.m.-8:40 p.m. Keynote Session: Connecting Stem Cells, Development, and Cancer 7:00 p.m.-7:10 p.m. Introduction and Welcome Geoffrey M. Wahl, Salk Institute for Biological Studies, La Jolla, CA, and Connie J. Eaves, BC Cancer Agency, Vancouver, BC, Canada 7:10 p.m.-7:55 p.m. Skin stem cells in morphogenesis and cancer Elaine V. Fuchs, Howard Hughes Medical Institute, Rockefeller University, New York, NY 7:55 p.m.-8:40 p.m. Role of Polycomb repressors in stem cells, cancer, and development Maarten van Lohuizen, The Netherlands Cancer Institute, Amsterdam, The Netherlands 8:40 p.m.-10:00 p.m. Opening Reception Friday, March 4 8:00 a.m.-10:05 a.m. Session 1: Stem Cells during Development Chairperson: Geoffrey M. Wahl, Salk Institute for Biological Studies, La Jolla, CA 8:00 a.m.-8:35 a.m. Developmental signaling in stem cells and cancer Tannishtha Reya, Duke University Medical Center, Durham, NC 8:35 a.m.-9:10 a.m. Mechanisms regulating hematopoietic stem cell development Hanna Mikkola, University of California, Los Angeles, CA 9:10 a.m.-9:45 a.m. Characterization of mammary stem cell activity and expression profiles during fetal development Geoffrey M. Wahl 9:45 a.m.-10:05 a.m. Hedgehog signaling specifies positional identity and fate in adult neural stem cells* Rebecca A. Ihrie, University of California, San Francisco, CA 10:05 a.m.-10:35 a.m.
    [Show full text]
  • A Stem Cell Reporter Based Platform to Identify and Target Drug Resistant Stem Cells in Myeloid Leukemia
    ARTICLE https://doi.org/10.1038/s41467-020-19782-x OPEN A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia Kyle Spinler1,2, Jeevisha Bajaj 1,2, Takahiro Ito 1,2, Bryan Zimdahl1,2,3, Michael Hamilton1,2, Armin Ahmadi1,2, Claire S. Koechlein1,2, Nikki Lytle1,2, Hyog Young Kwon 1,2, Ferdous Anower-E-Khuda4, Hao Sun 5, Allen Blevins1,2, Joi Weeks1,2, Marcie Kritzik1,2, Jan Karlseder 6, Mark H. Ginsberg 5, Pyong Woo Park7, ✉ Jeffrey D. Esko 4 & Tannishtha Reya 1,2,5,8 1234567890():,; Intratumoral heterogeneity is a common feature of many myeloid leukemias and a significant reason for treatment failure and relapse. Thus, identifying the cells responsible for residual disease and leukemia re-growth is critical to better understanding how they are regulated. Here, we show that a knock-in reporter mouse for the stem cell gene Musashi 2 (Msi2) allows identification of leukemia stem cells in aggressive myeloid malignancies, and provides a strategy for defining their core dependencies. Specifically, we carry out a high throughput screen using Msi2-reporter blast crisis chronic myeloid leukemia (bcCML) and identify several adhesion molecules that are preferentially expressed in therapy resistant bcCML cells and play a key role in bcCML. In particular, we focus on syndecan-1, whose deletion triggers defects in bcCML growth and propagation and markedly improves survival of transplanted mice. Further, live imaging reveals that the spatiotemporal dynamics of leukemia cells are critically dependent on syndecan signaling, as loss of this signal impairs their localization, migration and dissemination to distant sites.
    [Show full text]
  • Research Highlights Aacr-Su2c Research Alerts
    RESEARCH HIGHLIGHTS AACR-SU2C RESEARCH ALERTS GLIOBLASTOMA: NEW FINDINGS Title: “Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma” DOI: http://dx.doi.org/10.1038/s41591-018-0339-5 SU2C Author: Kurt Schalper, MD, PhD Title: “Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma” DOI: http://dx.doi.org/10.1038/s41591-019-0349-y SU2C Author: Raul Rabadan, PhD Grants: SU2C Dream Teams: SU2C-American Cancer Society Lung Cancer Dream Team, SU2C Colorectal Cancer Dream Team (Schalper); NSF/SU2C/V-Foundation Convergence Grant and Phillip A. Sharp Innovation in Collaboration Award (Rabadan) Published: Nature Medicine, Feb. 11, 2019 In studying the impact of immunotherapy on glioblastoma, SU2C-funded researchers have identified promising results on the use of the immunotherapy agents called PD-1 inhibitors, as well as clues to the origin of resistance to this class of drugs. Summary by the AACR: Glioblastoma is the most common form of brain cancer. Its prognosis remains dismal. Unfortunately, the standard first-line treatment of surgery and chemoradiation has limited efficacy. Immune checkpoint blockade has been a promising therapeutic strategy in many cancers, including melanoma and lung cancer. In light of this, researchers have explored whether immune checkpoint blockade, specifically PD-1 blockade, can also be effective in treating glioblastoma. SU2C-funded investigators have shared their contribution to this important effort in two research papers in the prestigious journal Nature Medicine. Kurt Schalper, MD, PhD, and his colleagues studied whether PD-1 inhibitors can also be used to treat glioblastoma patients before they undergo surgery (a treatment regimen called neoadjuvant therapy).
    [Show full text]
  • Image Based Detection and Targeting of Therapy Resistance in Pancreatic Adenocarcinoma
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2016 December 16. Published in final edited form as: Nature. ; 534(7607): 407–411. doi:10.1038/nature17988. Image based detection and targeting of therapy resistance in pancreatic adenocarcinoma Raymond G. Fox#1,2,3, Nikki K. Lytle#1,2,3, Dawn V. Jaquish3,4, Frederick D. Park1,2,3,5, Takahiro Ito1,2,3, Jeevisha Bajaj1,2,3, Claire S. Koechlein1,2,3, Bryan Zimdahl1,2,3, Masato Yano6,#, Janel Kopp2,7, Marcie Kritzik1,2,3, Jason Sicklick3,4, Maike Sander2,7, Paul M. Grandgenett8, Michael A. Hollingsworth8, Shinsuke Shibata6, Donald Pizzo9, Mark Valasek9, Roman Sasik10, Miriam Scadeng11, Hideyuki Okano6, Youngsoo Kim12, A. Robert MacLeod12, Andrew M. Lowy3,4, and Tannishtha Reya1,2,3 1Departments of Pharmacology and Medicine, University of California San Diego School of Medicine La Jolla, CA 2 Sanford Consortium for Regenerative Medicine, La Jolla, CA 3Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 4Department of Surgery, Division of Surgical Oncology, University of California San Diego School of Medicine, La Jolla, CA 5Department of Medicine, Division of Gastroenterology, University of California San Diego School of Medicine, La Jolla, CA 6Department of Physiology, Graduate School of Medicine, Keio University, Keio, Japan 7Department of Cellular and Molecular Medicine, University of California San Diego School of Medicine, La Jolla, CA 8Eppley Institute For Research in Cancer and Allied Diseases, Department of Pathology, University of Nebraska Medical Center, Omaha, NE 9 Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms Correspondence to: Andrew M.
    [Show full text]
  • A Stem Cell Reporter Based Platform to Identify and Target Drug Resistant Stem Cells in Myeloid Leukemia
    UC San Diego UC San Diego Previously Published Works Title A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia. Permalink https://escholarship.org/uc/item/7vk3p3vd Journal Nature communications, 11(1) ISSN 2041-1723 Authors Spinler, Kyle Bajaj, Jeevisha Ito, Takahiro et al. Publication Date 2020-11-26 DOI 10.1038/s41467-020-19782-x Peer reviewed eScholarship.org Powered by the California Digital Library University of California ARTICLE https://doi.org/10.1038/s41467-020-19782-x OPEN A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia Kyle Spinler1,2, Jeevisha Bajaj 1,2, Takahiro Ito 1,2, Bryan Zimdahl1,2,3, Michael Hamilton1,2, Armin Ahmadi1,2, Claire S. Koechlein1,2, Nikki Lytle1,2, Hyog Young Kwon 1,2, Ferdous Anower-E-Khuda4, Hao Sun 5, Allen Blevins1,2, Joi Weeks1,2, Marcie Kritzik1,2, Jan Karlseder 6, Mark H. Ginsberg 5, Pyong Woo Park7, ✉ Jeffrey D. Esko 4 & Tannishtha Reya 1,2,5,8 1234567890():,; Intratumoral heterogeneity is a common feature of many myeloid leukemias and a significant reason for treatment failure and relapse. Thus, identifying the cells responsible for residual disease and leukemia re-growth is critical to better understanding how they are regulated. Here, we show that a knock-in reporter mouse for the stem cell gene Musashi 2 (Msi2) allows identification of leukemia stem cells in aggressive myeloid malignancies, and provides a strategy for defining their core dependencies. Specifically, we carry out a high throughput screen using Msi2-reporter blast crisis chronic myeloid leukemia (bcCML) and identify several adhesion molecules that are preferentially expressed in therapy resistant bcCML cells and play a key role in bcCML.
    [Show full text]
  • Immunology Program Seminar Speakers 1994-1995 Through 2019-2020
    Immunology Program Seminar Speakers 1994-1995 through 2019-2020 Speaker Host Date Institution 2019-20 Harinder Singh PhD Hogan 9/4/19 University of Pittsburgh Brynna Burrell, PhD Alumni Career Series 10/2/19 Immune Tolerance Network Margaret M. McCarthy, PhD Singer 10/30/19 University of Maryland Peggy Petroff, PhD Moore 11/13/19 Michigan State University Susan Kovats, PhD Popova 12/4/19 Oklahoma Medical Research Foundation Claudia Kemper, PhD Wobus 3/11/20 NHLBI/NIH 2018-19 Miriam Merad, MD, PhD ZOU (co-sponsor) 9/6/18 Icahn School of Medicine at Mount Sinai Anand Balasubramani, PhD ZOU (co-sponsor) 9/6/18 AAAS Lenette Lu, MD, PhD MARKOVITZ (co-sponsor) 9/12/18 Massachusettes General Hospital Michail Lionakis, MD, ScD MARKOVITZ (co-sponsor) 10/10/18 NIH/NIAID Brian Rudd, MPH, PhD LUKACS 11/7/18 Cornell University Fred Finkelman, MD HOGAN 11/28/18 Cincinnati Children’s Hospital Michael Barry, PhD MUNIE 12/5/18 Mayo Clinic John Varga, MD FOX 1/9/19 Northwestern University Rachael Clark, MD GUDJONSSON 1/16/19 Brigham & Women’s Hospital Irah King, PhD SEGAL 3/20/19 McGill University Wilson Wong, PhD LEI 5/1/19 Boston University Thomas Rothstein, MD, PhD MAO-DRAAYER 5/29/19 Western Michigan University 2017-18 Avery August, PhD LUKACS 9/6/17 Cornell University Javier Carrero, PhD G. MARTINEZ-COLON 9/27/17 Washington University – St. Louis Russell Jones, PhD C. CHANG 10/11/17 McGill University John Cambier, PhD GRIGOROVA 11/15/17 University of Colorado Bernard Fox, PhD LI 2/7/18 Oregon Health & Science University Tannishtha Reya, PhD O’RIORDAN 2/21/18 University of California, San Diego Richard Bucala, MD GOLDSTEIN 3/21/18 Yale University Kristin Hogquist, PhD CARTY 4/4/18 University of Minnesota 2016-17 George Dubyak, PhD KAHLENBERG 9/7/16 Case Western University Daniel Stetson, PhD O’RIORDAN 9/21/16 University of Washington Alyssa Hasty, PhD D.
    [Show full text]